Search Results

BPGbio, Inc. today announced the application of its NAi Interrogative Biology® Platform across several drug and diagnostic applications, following successful collaborations with Stanford University, University of Tennessee, Oak Ridge National Laboratory, and several leading hospitals across Mexico.

Biosenta Inc. (CSE: ZRO) (“Biosenta” or the “Company”) announces that it has entered into an agreement with Oak Hill Financial Inc. (“Oak Hill”) to provide business

Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) (“Hemostemix” or the “Company”) is pleased to announce the non-exclusive engagement of Oak Hill Asset Management Inc. (“OHAM”), an Exempt Market Dealer to provide capital markets advice related to the Company’s capital markets strategy.

Sterling Ridge Orthopaedics & Sports Medicine proudly announces a groundbreaking achievement in orthopaedic surgery with Dr. Paul Chin, MD, PhD, FAAOS, FAANA, at the forefront.

Oak Hill Bio and Chiesi announced that the first patient has been enrolled in a resumed Phase 2b clinical study to assess the efficacy and safety of OHB-607, an investigational drug candidate being developed to treat complications of extremely premature birth, including bronchopulmonary dysplasia, a serious condition for which there are no approved therapies.

Carl Zeiss Industrial Metrology, LLC has partnered with Oak Ridge National Laboratory on a project chosen to receive funding through the U.S. Department of Energy’s Technology Commercialization Fund project solicitation.

Chiesi Group and Oak Hill Bio will collaborate closely to develop OHB-607, a clinical-stage investigational drug candidate being developed to treat complications of extremely premature birth.